XBRANE Share Price Performance
SEK 0
-34.92 (-100.00%)
Price SEK 0
Fair ValueSEK 15.50
Share Pricen/a
Xbrane Biopharma AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
XBRANE Community Narratives
AN
Fair Value
·Fair Value SEK 15.5 34.5% undervalued intrinsic discount
Biosimilar Adoption And Cost Reductions Will Support Long Term Earnings Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value SEK 8 26.9% overvalued intrinsic discount
Retinal Biosimilar Headwinds Will Tighten Margins Before Cost Cuts Start To Help
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 17 40.3% undervalued intrinsic discount
Expanded Biosimilar Pipeline And Profit Sharing Will Support Stronger Long Term Outcomes
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Retinal Biosimilar Headwinds Will Tighten Margins Before Cost Cuts Start To Help
Catalysts About Xbrane Biopharma Xbrane Biopharma develops and co develops biosimilar drugs, with current programs focused on ophthalmology and immuno oncology. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 8
26.9% overvalued intrinsic discount
Fair Value
Profit Margin
20.1%
Future PE
5.43x
Price in 2029
SEK 5.33
Expanded Biosimilar Pipeline And Profit Sharing Will Support Stronger Long Term Outcomes
Catalysts About Xbrane Biopharma Xbrane Biopharma develops and co-develops biosimilar medicines, with a current focus on ophthalmology and oncology products. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 17
40.3% undervalued intrinsic discount
Fair Value
Profit Margin
18.8%
Future PE
13.61x
Price in 2029
SEK 11.07
Biosimilar Adoption And Cost Reductions Will Support Long Term Earnings Recovery
Catalysts About Xbrane Biopharma Xbrane Biopharma develops and commercializes biosimilar medicines, with a focus on ophthalmology and oncology products in partnership driven models. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 15.5
34.5% undervalued intrinsic discount
Fair Value
Profit Margin
0.053%
Future PE
15.86x
Price in 2028
SEK 0.1
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Retinal Biosimilar Headwinds Will Tighten Margins Before Cost Cuts Start To Help
Fair Value: SEK 8 26.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanded Biosimilar Pipeline And Profit Sharing Will Support Stronger Long Term Outcomes
Fair Value: SEK 17 40.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Biosimilar Adoption And Cost Reductions Will Support Long Term Earnings Recovery
Fair Value: SEK 15.5 34.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Xbrane Biopharma AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 30, 2026
- -3.59
- 13.94%
- -88.84%
- 10.7%
About XBRANE
- Founded
- 2008
- Employees
- 29
- CEO
- WebsiteView website
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
